Tag: Obesity
Study IDs Barriers to GLP-1 Receptor Agonist Use in Adolescents, Young Adults
A number of young adults eligible for GLP-1 RAs are uninsured
Polygenic Scores for BMI Can Improve Prediction of Future Obesity
Children with higher polygenic scores showed accelerated BMI gain from age 2.5 years to adolescence in ALSPAC study
Prediabetes Risk Doubled for Asian, Pacific Islander Teens With Overweight, Obesity
Findings show some variation by Asian subgroup
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
Significantly lower risks seen for those receiving GLP-1 receptor agonists compared with other antidiabetic drugs
Long-Term Obesity Linked to Expression of Aging Biomarkers
Association seen for long-term obesity with adulthood expression of biomarkers denoting antagonistic and integrative aging hallmarks
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
Higher protein intake may be protective against muscle loss, which is tied to less improvement in glucose homeostasis
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
Highest mortality rates seen among older adults, rural populations, and those in the Midwest
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
Highest mortality rates seen among older adults, rural populations, and those in the Midwest
